Drug Profile
HEC 80797
Alternative Names: HEC80797Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Mantle-cell lymphoma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Breast-cancer in China
- 28 Sep 2020 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in China
- 25 Aug 2016 Preclinical trials in Breast cancer in China (unspecified route) prior to August 2016 (HEC Pharm pipeline, August 2016)